NORTHBROOK, Ill., Jan. 8, 2020 /PRNewswire/ — Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for Mycamine (micafungin for injection) in support of the…Original Article
FDA Approves Expanded Indication of Mycamine (micafungin for injection) for the Treatment of Invasive Candidiasis in Pediatric Patients Less Than 4 Months of Age
